ReviewMolecular biology reports2026
CC chemokines in epithelial ovarian cancer: orchestrating the metastatic microenvironment and therapy resistance.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Peritoneal metastasis is a major contributor to progression, recurrence, and treatment failure in epithelial ovarian cancer (EOC) and is closely associated with dynamic remodeling of the peritoneal tumor microenvironment (TME). Interactions among tumor cells, ascites, the omental niche, stromal components, and immune cells collectively shape metastatic dissemination and therapeutic response. CC chemokines are important regulators of these processes, linking immune-cell trafficking with tumor-cell plasticity, metabolic adaptation, angiogenesis, and therapy resistance. This review summarizes the roles of CC chemokines in EOC progression within a chemokine-driven peritoneal niche remodeling framework encompassing four key stages: early dissemination, survival in ascites, omental colonization, and therapy resistance. Among the major signaling axes, CCL2-CCR2 is primarily associated with monocyte recruitment and myeloid-dominant immunosuppression, whereas CCL5-CCR5 is linked to stromal immune regulation and cancer stem-like phenotypes. Additional pathways, including CCL18, CCL20-CCR6, CCL22-CCR4, and CCL1-CCR8, contribute to T-regulatory cell recruitment, immune suppression, and hypoxia-associated responses. The review further discusses the limited efficacy of chemokine-targeted monotherapy, highlighting challenges posed by signaling redundancy, compensatory pathways, spatial heterogeneity, and insufficient biomarker-guided patient selection. Recent advances in single-cell and spatial transcriptomic technologies have improved the characterization of compartment-specific chemokine programs within the EOC microenvironment. Finally, emerging combination strategies involving chemokine blockade together with immune checkpoint inhibitors, metabolic interventions, PARP inhibitors, and ferroptosis-related approaches are evaluated. However, successful clinical translation will require precise patient stratification, effective toxicity management, and validation in clinically annotated cohorts.
Indexed as
Identifiers
42377632What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.